Skip to main content

Predictive Genomic Biomarkers Methods for Combination Bevacizumab (Avastin) Therapy in Metastatic Colorectal Cancer

Objective

In recent years the treatment paradigm for metastatic colorectal cancer (mCRC) has evolved in complexity to include newly developed targeted therapeutics. In 2004 bevacizumab (bvz) [Avastin] became the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced metastatic colorectal cancer. Nevertheless, over the past six year period emerging data now indicates that bvz fails to produce an enduring clinical response in a high proportion of patients. Delivery of the drug as part of a combination treatment regimen in mCRC elicits transitory improvements in the form of tumour stasis or shrinkage. Inevitably however, the tumours begin to re-grow and the disease progresses. It is now universally agreed that the future use of bvz in mCRC (and other cancers) is likely to be greatly influenced by the availability of predictive biomarkers to allow selection of patients who will attain the greatest benefit. The ANGIOPREDICT paradigm relies on a modular platform for the integrated discovery and validation of predictive pharmacogenomic biomarkers for combination bvz therapy in mCRC. Through initiation of a multi-centre clinical trial, early discovery findings will be validated for markers of Intrinsic Resistance to therapy. Parallel optimization of companion in vitro diagnostic tests (IVDs) through exploitation of proven SME development and validation strategies will ensure a cross-sectoral benefit to the cancer patient, prescribing physician and more broadly, across European and global public health networks. Crucially, leading SME partners will expand business portfolios into a well-defined market, progress novel intellectual property and access several in-licensing opportunities. ANGIOPREDICT uniquely unites world-class molecular diagnostic biomarker discovery SMEs with leading clinical and academic entities to identify a new generation of individualized methods for predicting response to combination bvz therapy.

Field of science

  • /medical and health sciences/clinical medicine/cancer/colorectal cancer
  • /medical and health sciences/health sciences/public and environmental health

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
Address
Saint Stephen's Green 123
2 Dublin
Ireland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 199 280
Administrative Contact
Annette Byrne (Dr.)

Participants (10)

VIB VZW
Belgium
EU contribution
€ 677 500
Address
Rijvisschestraat 120
9052 Zwijnaarde - Gent
Activity type
Research Organisations
Administrative Contact
Rik Audenaert (Mr.)
EPIGENOMICS AG
Germany
EU contribution
€ 794 625
Address
Kleine Praesidentenstr 1
10178 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Annett Freitag (Ms.)
SOMANTIX BV
Netherlands
EU contribution
€ 587 800
Address
Professor Bronkhorstlann 10-92
3723 MB Bilthoven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Laurens Van Der Flier (Dr.)
ONCOMARK LIMITED
Ireland
EU contribution
€ 697 800
Address
172 Rathgar Road Rathgar
Dublin 6 Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mairin Rafferty (Dr.)
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
Netherlands
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
B Ylstra (Dr.)
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Germany
EU contribution
€ 541 950,75
Address
Seminarstrasse 2
69117 Heidelberg
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Matthias Ebert (Prof.)
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
Ireland
EU contribution
€ 634 800
Address
Belfield
4 Dublin
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Donal Doolan (Mr.)
CANCER TRIALS IRELAND CLG
Ireland
EU contribution
€ 277 200
Address
Innovation House Dcu Alpha Finglas Road Old
D11 KXN4 Dublin 11
Activity type
Other
Administrative Contact
Verena Murphy (Dr.)
PINTAIL LTD
Ireland
EU contribution
€ 152 000
Address
Springhill Avenue 77
A94 K542 Blackrock
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Ciaran Clissmann
STICHTING VU
Netherlands
EU contribution
€ 436 200
Address
De Boelelaan 1105
1081 HV Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Bauke Ylstra (Dr.)